← All trials

NCT07227454

Phase 3Interventional

Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.

View on ClinicalTrials.gov ↗

Timeline

Start date
Nov 20, 2025
Primary completion
Apr 9, 2031
Completion date
Sep 15, 2031
First posted
Nov 12, 2025
Last posted
Nov 12, 2025
Enrollment
258
Arms / groups
2 / —
Source
AACT · ctgov ingestion

Drugs studied

Indications studied

CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.